Trials / Active Not Recruiting
Active Not RecruitingNCT06028009
PRP Injections for Genitourinary Syndrome of Menopause
Vaginal Injection of Platelet Rich Plasma (PRP) for the Genitourinary Syndrome of Menopause (GSM)
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Medstar Health Research Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Platelet-rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. Injection of PRP stimulates cell growth and can has been proven safe and effective for uses in orthopedics, dermatology, and gynecology. Despite the relative paucity of data, the use of PRP as a therapy for sexual dysfunction and genitourinary symptoms in the setting of menopause has been patented as the O-Shot and V-Shot. This is a single-blinded randomized control trial to determine if PRP injections into the anterior vaginal wall improve sexual functioning in women diagnosed with the genitourinary syndrome of menopause (GSM) characterized by vaginal dryness/irritation.
Conditions
- PRP
- Sexual Function Disturbances
- Genitourinary Syndrome of Menopause
- Postmenopausal Symptoms
- Vaginal Atrophy
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Injection of platelet-rich plasma | Injection of autologous platelet-rich plasma into anterior vaginal wall |
| PROCEDURE | Injection of saline | Injection of sterile normal saline into anterior vaginal wall |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2025-12-31
- Completion
- 2026-04-30
- First posted
- 2023-09-07
- Last updated
- 2025-11-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06028009. Inclusion in this directory is not an endorsement.